A critical role of acute bronchoconstriction in the mortality associated with high-dose sarin inhalation: Effects of epinephrine and oxygen therapies

Toxicology and Applied Pharmacology

Volumn 274, Issue 2, 2014, Pages 200-208

  Gundavarapu, Sravanthi ^a   Zhuang, Jianguo ^a   Barrett, Edward G ^a   Xu, Fadi ^a   Russell, Robert G ^a   Sopori, Mohan L ^a  

^a LOVELACE RESPIRATORY RESEARCH INSTITUTE   (United States)

Author keywords

Bronchoconstriction; Epinephrine; Inflammatory cytokines; Oxygen therapy; Respiratory function; Sarin

Indexed keywords

ADRENALIN; EOTAXIN; GELATINASE A; GELATINASE B; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; OXYGEN; SARIN; TUMOR NECROSIS FACTOR ALPHA;

ACUTE DISEASE; AIRWAY RESISTANCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRONCHOCONSTRICTION; BRONCHODILATATION; CONTROLLED STUDY; CYTOKINE RESPONSE; DENSITOMETRY; DRUG EFFECT; HISTOPATHOLOGY; HYPEROXIA; HYPOXIA; LD 50; LUNG ALVEOLUS EPITHELIUM; LUNG EPITHELIUM INJURY; LUNG GAS EXCHANGE; LUNG INJURY; LUNG LAVAGE; MALE; MORTALITY; NONHUMAN; OXYGEN THERAPY; PROTEIN CONTENT; PROTEIN EXPRESSION; RAT; SURVIVAL; TISSUE REPAIR;

EID: 84890883159     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2013.11.007     Document Type: Article

References (50)

1. Abou-Donia M.B. Organophosphorus ester-induced chronic neurotoxicity. Arch. Environ. Health 2003, 58:484-497.
2. Albuquerque E.X., Pereira E.F., Aracava Y., Fawcett W.P., Oliveira M., Randall W.R., Hamilton T.A., Kan R.K., Romano J.A., Adler M. Effective countermeasure against poisoning by organophosphorus insecticides and nerve agents. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:13220-13225.
3. Baay-Guzman G.J., Bebenek I.G., Zeidler M., Hernandez-Pando R., Vega M.I., Garcia-Zepeda E.A., Antonio-Andres G., Bonavida B., Riedl M., Kleerup E., Tashkin D.P., Hankinson O., Huerta-Yepez S. HIF-1 expression is associated with CCL2 chemokine expression in airway inflammatory cells: implications in allergic airway inflammation. Respir. Res. 2012, 13:60.
4. Bakowska J., Adamson I.Y. Collagenase and gelatinase activities in bronchoalveolar lavage fluids during bleomycin-induced lung injury. J. Pathol. 1998, 185:319-323.
5. Buels K.S., Fryer A.D. Muscarinic receptor antagonists: effects on pulmonary function. Handb. Exp. Pharmacol. 2012, 317-341.
6. Chakrabarti S., Patel K.D. Matrix metalloproteinase-2 (MMP-2) and MMP-9 in pulmonary pathology. Exp. Lung Res. 2005, 31:599-621.
7. Chen P., Parks W.C. Role of matrix metalloproteinases in epithelial migration. J. Cell. Biochem. 2009, 108:1233-1243.
8. Corbel M., Boichot E., Lagente V. Role of gelatinases MMP-2 and MMP-9 in tissue remodeling following acute lung injury. Braz. J. Med. Biol. Res. 2000, 33:749-775.
9. da Rosa D.P., Forgiarini L.F., Baronio D., Feijo C.A., Martinez D., Marroni N.P. Simulating sleep apnea by exposure to intermittent hypoxia induces inflammation in the lung and liver. Mediators Inflamm. 2012, 2012:879419.
10. Davey A., McAuley D.F., O'Kane C.M. Matrix metalloproteinases in acute lung injury: mediators of injury and drivers of repair. Eur. Respir. J. 2011, 38:959-970.
11. Dela Cruz C.S., Kang M.J., Cho W.K., Lee C.G. Transgenic modelling of cytokine polarization in the lung. Immunology 2011, 132:9-17.
12. Eichler W., Bechtel J.F., Schumacher J., Wermelt J.A., Klotz K.F., Bartels C. A rise of MMP-2 and MMP-9 in bronchoalveolar lavage fluid is associated with acute lung injury after cardiopulmonary bypass in a swine model. Perfusion 2003, 18:107-113.
13. Finlay G.A., O'Driscoll L.R., Russell K.J., D'Arcy E.M., Masterson J.B., FitzGerald M.X., O'Connor C.M. Matrix metalloproteinase expression and production by alveolar macrophages in emphysema. Am. J. Respir. Crit. Care Med. 1997, 156:240-247.
14. Gundavarapu S., Wilder J.A., Mishra N.C., Rir-Sima-Ah J., Langley R.J., Singh S.P., Saeed A.I., Jaramillo R.J., Gott K.M., Pena-Philippides J.C., Harrod K.S., McIntosh J.M., Buch S., Sopori M.L. Role of nicotinic receptors and acetylcholine in mucous cell metaplasia, hyperplasia, and airway mucus formation in vitro and in vivo. J. Allergy Clin. Immunol. 2012, 130:770-780. (e711).
15. Gushima Y., Ichikado K., Suga M., Okamoto T., Iyonaga K., Sato K., Miyakawa H., Ando M. Expression of matrix metalloproteinases in pigs with hyperoxia-induced acute lung injury. Eur. Respir. J. 2001, 18:827-837.
16. Henderson R.F., Barr E.B., Blackwell W.B., Clark C.R., Conn C.A., Kalra R., March T.H., Sopori M.L., Tesfaigzi Y., Menache M.G., Mash D.C. Response of rats to low levels of sarin. Toxicol. Appl. Pharmacol. 2002, 184:67-76.
17. Holstege C.P., Kirk M., Sidell F.R. Chemical warfare. Nerve agent poisoning. Crit. Care Clin. 1997, 13:923-942.
18. Huerta-Yepez S., Baay-Guzman G.J., Bebenek I.G., Hernandez-Pando R., Vega M.I., Chi L., Riedl M., Diaz-Sanchez D., Kleerup E., Tashkin D.P., Gonzalez F.J., Bonavida B., Zeidler M., Hankinson O. Hypoxia inducible factor promotes murine allergic airway inflammation and is increased in asthma and rhinitis. Allergy 2011, 66:909-918.
19. Kadar T., Shapira S., Cohen G., Sahar R., Alkalay D., Raveh L. Sarin-induced neuropathology in rats. Hum. Exp. Toxicol. 1995, 14:252-259.
20. Kalra R., Singh S.P., Razani-Boroujerdi S., Langley R.J., Blackwell W.B., Henderson R.F., Sopori M.L. Subclinical doses of the nerve gas sarin impair T cell responses through the autonomic nervous system. Toxicol. Appl. Pharmacol. 2002, 184:82-87.
21. Kassa J., Misik J., Karasova J.Z. A comparison of the potency of a novel bispyridinium oxime K203 and currently available oximes (obidoxime, HI-6) to counteract the acute neurotoxicity of sarin in rats. Basic Clin. Pharmacol. Toxicol. 2012, 111:333-338.
22. Kim K.K., Wei Y., Szekeres C., Kugler M.C., Wolters P.J., Hill M.L., Frank J.A., Brumwell A.N., Wheeler S.E., Kreidberg J.A., Chapman H.A. Epithelial cell alpha3beta1 integrin links beta-catenin and Smad signaling to promote myofibroblast formation and pulmonary fibrosis. J. Clin. Invest. 2009, 119:213-224.
23. Kim H.J., Jeong J.S., Kim S.R., Park S.Y., Chae H.J., Lee Y.C. Inhibition of endoplasmic reticulum stress alleviates lipopolysaccharide-induced lung inflammation through modulation of NF-kappaB/HIF-1alpha signaling pathway. Sci. Rep. 2013, 3:1142.
24. Leikin J.B., Thomas R.G., Walter F.G., Klein R., Meislin H.W. A review of nerve agent exposure for the critical care physician. Crit. Care Med. 2002, 30:2346-2354.
25. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25:402-408.
26. Mak J.C., Barnes P.J. Autoradiographic visualization of muscarinic receptor subtypes in human and guinea pig lung. Am. Rev. Respir. Dis. 1990, 141:1559-1568.
27. Malemud C.J. Matrix metalloproteinases (MMPs) in health and disease: an overview. Front. Biosci. 2006, 11:1696-1701.
28. Moelants E.A., Mortier A., Van Damme J., Proost P. Regulation of TNF-alpha with a focus on rheumatoid arthritis. Immunol. Cell Biol. 2013, 91:393-401.
29. Nakajima T., Ohta S., Fukushima Y., Yanagisawa N. Sequelae of sarin toxicity at one and three years after exposure in Matsumoto, Japan. J. Epidemiol. 1999, 9:337-343.
30. Niven A.S., Roop S.A. Inhalational exposure to nerve agents. Respir. Care Clin. N. Am. 2004, 10:59-74.
31. Pant S.C., Vijayaraghavan R., Das Gupta S. Sarin induced lung pathology and protection by standard therapy regime. Biomed. Environ. Sci. 1993, 6:103-111.
32. Pena-Philippides J.C., Razani-Boroujerdi S., Singh S.P., Langley R.J., Mishra N.C., Henderson R.F., Sopori M.L. Long- and short-term changes in the neuroimmune-endocrine parameters following inhalation exposures of F344 rats to low-dose sarin. Toxicol. Sci. 2007, 97:181-188.
33. Racke K., Juergens U.R., Matthiesen S. Control by cholinergic mechanisms. Eur. J. Pharmacol. 2006, 533:57-68.
34. Rohwer N., Cramer T. Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways. Drug Resist. Updat. 2011, 14:191-201.
35. Romagnani P., Crescioli C. CXCL10: a candidate biomarker in transplantation. Clin. Chim. Acta 2012, 413:1364-1373.
36. Sandau K.B., Zhou J., Kietzmann T., Brune B. Regulation of the hypoxia-inducible factor 1alpha by the inflammatory mediators nitric oxide and tumor necrosis factor-alpha in contrast to desferroxamine and phenylarsine oxide. J. Biol. Chem. 2001, 276:39805-39811.
37. Sarzi-Puttini P., Atzeni F., Shoenfeld Y., Ferraccioli G. TNF-alpha, rheumatoid arthritis, and heart failure: a rheumatological dilemma. Autoimmun. Rev. 2005, 4:153-161.
38. Savard C.E., Blinman T.A., Choi H.S., Lee S.K., Pandol S.J., Lee S.P. Expression of cytokine and chemokine mRNA and secretion of tumor necrosis factor-alpha by gallbladder epithelial cells: response to bacterial lipopolysaccharides. BMC Gastroenterol. 2002, 2:23.
39. Sidell F.R. Clinical effects of organophosphorus cholinesterase inhibitors. J. Appl. Toxicol. 1994, 14:111-113.
40. Singh S.P., Gundavarapu S., Pena-Philippides J.C., Rir-Sima-ah J., Mishra N.C., Wilder J.A., Langley R.J., Smith K.R., Sopori M.L. Prenatal secondhand cigarette smoke promotes Th2 polarization and impairs goblet cell differentiation and airway mucus formation. J. Immunol. 2011, 187:4542-4552.
41. Szabo H., Novak Z., Bauer H., Szatmari E., Farkas A., Wejksza K., Orbok A., Wilhelm I., Krizbai I.A. Regulation of proteolytic activity induced by inflammatory stimuli in lung epithelial cells. Cell. Mol. Biol. (Noisy-le-grand) 2005, (51 Suppl.):OL729-OL735.
42. Szinicz L. History of chemical and biological warfare agents. Toxicology 2005, 214:167-181.
43. Tang C.M., Yu J. Hypoxia-inducible factor-1 as a therapeutic target in cancer. J. Gastroenterol. Hepatol. 2013, 28:401-405.
44. Toth M., Sohail A., Fridman R. Assessment of gelatinases (MMP-2 and MMP-9) by gelatin zymography. Methods Mol. Biol. 2012, 878:121-135.
45. Wang Z., Zheng T., Zhu Z., Homer R.J., Riese R.J., Chapman H.A., Shapiro S.D., Elias J.A. Interferon gamma induction of pulmonary emphysema in the adult murine lung. J. Exp. Med. 2000, 192:1587-1600.
46. Warwick G., Thomas P.S., Yates D.H. Non-invasive biomarkers in exacerbations of obstructive lung disease. Respirology 2013, 18:874-884.
47. Weinbroum A.A. Pathophysiological and clinical aspects of combat anticholinesterase poisoning. Br. Med. Bull. 2004, 72:119-133.
48. Wood J.R. Chemical defense. J. Am. Med. Assoc. 1951, 145:1264-1267.
49. Zhang W., Shibamoto T., Kuda Y., Ohmukai C., Kurata Y. Pulmonary vasoconstrictive and bronchoconstrictive responses to anaphylaxis are weakened via beta2-adrenoceptor activation by endogenous epinephrine in anesthetized rats. Anesthesiology 2011, 114:614-623.
50. Zhuang J., Xu F., Campen M.J., Zhang C., Pena-Philippides J.C., Sopori M.L. Inhalation of the nerve gas sarin impairs ventilatory responses to hypercapnia and hypoxia in rats. Toxicol. Appl. Pharmacol. 2008, 232:440-447.